PhaseBio Might Have To Return Global Rights To Its Lead Program

Benzinga

2022/09/28

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition.
Formerly known as PB2452, bentracimab reverses the effects of AstraZeneca Plc's (NASDAQ:AZN) blood thinner Brilinta (ticagrelor)
In January 2020, PhaseBio announced a financing and co-development partnership with SFJ Pharmaceuticals. PhaseBio retains exclusive worldwide commercial rights.
In December 2021 annual filing, PhaseBio listed an explanatory paragraph relating to its substantial doubt about its ability to continue as a going concern.
Related: Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B.
The company engaged a financial advisor in Q1 of 2022.
PhaseBio received several offers for the licensing and/or acquiring certain commercial rights to bentracimab.
Each offer, however, would have required SFJ to refrain from terminating the co-development agreement and asserting accelerated termination payment obligations by PhaseBio. Hence, it could not move forward with any such alternatives.
Price Action: PHAS shares traded 47.37% lower at $0.40 during pre-market trading on Wednesday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2270951784"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2270951784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2270951784?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-28 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2270951784","market":"hk","top_or_hot":-1,"title":"PhaseBio Might Have To Return Global Rights To Its Lead Program","media":"Benzinga","content":"<html><body><ul>\n<li><strong>PhaseBio Pharmaceuticals Inc</strong> (NASDAQ:PHAS) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition.</li>\n<li>Formerly known as PB2452, bentracimab reverses the effects of <strong>AstraZeneca Plc's</strong> (NASDAQ:AZN) blood thinner Brilinta (ticagrelor) </li>\n<li>In January 2020, PhaseBio announced a financing and co-development partnership with SFJ Pharmaceuticals. PhaseBio retains exclusive worldwide commercial rights.</li>\n<li>In December 2021 annual filing, PhaseBio listed an explanatory paragraph relating to its substantial doubt about its ability to continue as a going concern. </li>\n<li><strong><em>Related:</em></strong><em> </em><em>Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B</em><em>.</em></li>\n<li>The company engaged a financial advisor in Q1 of 2022.</li>\n<li>PhaseBio received several offers for the licensing and/or acquiring certain commercial rights to bentracimab.</li>\n<li>Each offer, however, would have required SFJ to refrain from terminating the co-development agreement and asserting accelerated termination payment obligations by PhaseBio. Hence, it could not move forward with any such alternatives.</li>\n<li><strong>Price Action:</strong> PHAS shares traded 47.37% lower at $0.40 during pre-market trading on Wednesday.</li>\n</ul>\n</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PhaseBio Might Have To Return Global Rights To Its Lead Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhaseBio Might Have To Return Global Rights To Its Lead Program\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2022-09-28 21:06</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><ul>\n<li><strong>PhaseBio Pharmaceuticals Inc</strong> (NASDAQ:PHAS) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition.</li>\n<li>Formerly known as PB2452, bentracimab reverses the effects of <strong>AstraZeneca Plc's</strong> (NASDAQ:AZN) blood thinner Brilinta (ticagrelor) </li>\n<li>In January 2020, PhaseBio announced a financing and co-development partnership with SFJ Pharmaceuticals. PhaseBio retains exclusive worldwide commercial rights.</li>\n<li>In December 2021 annual filing, PhaseBio listed an explanatory paragraph relating to its substantial doubt about its ability to continue as a going concern. </li>\n<li><strong><em>Related:</em></strong><em> </em><em>Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B</em><em>.</em></li>\n<li>The company engaged a financial advisor in Q1 of 2022.</li>\n<li>PhaseBio received several offers for the licensing and/or acquiring certain commercial rights to bentracimab.</li>\n<li>Each offer, however, would have required SFJ to refrain from terminating the co-development agreement and asserting accelerated termination payment obligations by PhaseBio. Hence, it could not move forward with any such alternatives.</li>\n<li><strong>Price Action:</strong> PHAS shares traded 47.37% lower at $0.40 during pre-market trading on Wednesday.</li>\n</ul>\n</body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美國抗疫概念","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/22/09/29049003/phasebio-might-have-to-return-global-rights-to-its-lead-program","article_id":"2270951784","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2270951784","pubTimestamp":1664370380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"\n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","QLD":"2倍做多纳斯达克100指数ETF-ProShares","PSQ":"做空纳斯达克100指数ETF-ProShares",".IXIC":"NASDAQ Composite","AZN":"阿斯利康","QQQ":"纳指100ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","BK4139":"生物科技","SQQQ":"纳指三倍做空ETF","TQQQ":"纳指三倍做多ETF","BK4007":"制药"},"translate_title":"PhaseBio可能不得不将全球权利归还给其牵头项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.65,"MNQmain":0.6,"PSQ":0.6,"QQQ":0.6,"NQmain":0.6,"QID":0.6,"AZN":0.9,"SQQQ":0.6,"TQQQ":0.6,"PHAS":0.9,"QLD":0.6},"content_text":"PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition.\nFormerly known as PB2452, bentracimab reverses the effects of AstraZeneca Plc's (NASDAQ:AZN) blood thinner Brilinta (ticagrelor) \nIn January 2020, PhaseBio announced a financing and co-development partnership with SFJ Pharmaceuticals. PhaseBio retains exclusive worldwide commercial rights.\nIn December 2021 annual filing, PhaseBio listed an explanatory paragraph relating to its substantial doubt about its ability to continue as a going concern. \nRelated: Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B.\nThe company engaged a financial advisor in Q1 of 2022.\nPhaseBio received several offers for the licensing and/or acquiring certain commercial rights to bentracimab.\nEach offer, however, would have required SFJ to refrain from terminating the co-development agreement and asserting accelerated termination payment obligations by PhaseBio. Hence, it could not move forward with any such alternatives.\nPrice Action: PHAS shares traded 47.37% lower at $0.40 during pre-market trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}